Moderna's COVID-19 Vaccine Retains Antibodies Against Variants For 6 Months

Moderna Inc MRNA announced the publication of a new study showing that its COVID-19 vaccine led to durable antibody levels against variants of concern.
According to the report published in the journal Science, most individuals retained binding and neutralizing antibodies against variants for six months following the second dose.
Alpha, Beta, Gamma, Delta, Epsilon, and Iota were some of the variants studied by the researchers.
A waning antibody effect against SARS-CoV-2 spike variants was seen in the oldest subjects at Day 209.
Though the differences were small, many in the oldest age group maintained neutralizing activity against variants even after six months.
“We expect that these data and the growing body of real-world evidence will help inform health regulators’ approaches to how and when to administer additional boosting doses,” Moderna CEO Stéphane Bancel said.
The data support the durable efficacy of 93% seen through six months.
On Thursday, the FDA approved the third dose of COVID-19 vaccine from Moderna and Pfizer Inc PFE - BioNTech SE BNTX for immunocompromised individuals.
Price Action: MRNA shares are up 1.93% at $398.99 during the premarket session on the last check Friday.
Photo by Spencer Davis from Pixabay